Dr. Park's research involves cutting-edge application of nanotechnology to improve the diagnosis and treatment of primary liver cancer. In this novel approach, Glypican-3 antibodies are used to target and deliver Zirconium-89, greatly enhancing the diagnostic sensitivity and specificity of hepatocellular carcinoma on positron emission tomography. This Glypican-3 antibody targeting technology is also being used with an alpha-particle emitting radioisotope, Astatine-211 as an innovative therapy for hepatocellular carcinoma.
Serial decay-corrected whole-body micro-PET images of mouse bearing (A) large HepG2 tumor (3.8 mm), and (B) small HepG2 tumor (< 1 mm). Blue arrowhead indicates tumor location. (C) Average tumor and liver activity obtained from micro-PET data for mouse with large HepG2 tumor, and (D) mouse with small HepG2 tumor.
(A) IVIS luminescent images prior to administration of 89Zr-aGPC3. (B) Selected micro-PET images of the same animals showing tumor concordance in HepG2 tumor-bearing animals, and lack of tumor uptake in RH7777, blocked, and heat-denatured controls. Signal saturation was permitted to enable comparisons between animals. Blue arrowheads indicate tumor location, red arrow indicates spleen. (C) Day 7 decay-corrected biodistribution of 89Zr-aGPC3 confirming low liver tumor uptake in RH7777, blocked, and heat-denatured controls.
Satoshi Minoshima, MD, PhD, Professor, UW Department of Radiology Kimberly J. Riehle, MD, Assistant Professor, UW Department of Surgery D. Scott Wilbur, PhD, Professor, UW Department of Radiation Oncology Matthew Yeh, MD, PhD, Professor, UW Department of Pathology Raymond S. Yeung, MD, Professor, UW Department of Surgery Miqin Zhang, PhD, Professor, UW Department of Materials Science and Engineering
Benson AB 3rd, D'Angelica MI, Abrams TA, Are C, Bloomston PM, Chang DT, Clary BM, Covey AM, Ensminger WD, Iyer R, Kelley RK, Linehan D, Malafa MP, Meranze SG, Park JO, Pawlik T, Posey JA, Scaife C, Schefter T, Sigurdson ER, Tian GG, Vauthey JN, Venook AP, Yen Y, Zhu AX, Hoffmann KG, McMillian NR, Sundar H. Hepatobiliary cancers, version 2.2014. J Natl Compr Canc Netw. 2014 Aug;12(8):1152-82. PMID: 25099447
Shin DS, Ingraham CR, Dighe MK, Wang C, Vaidya S, Moshiri M, Lall C, Park JO, Bhargava P. Surgical resection of a malignant liver lesion: what the surgeon wants the radiologist to know. AJR Am J Roentgenol. 2014 Jul;203(1):W21-33. doi: 10.2214/AJR.13.11701. Review. PMID: 24951226
Riehle KJ, Yeh MM, Yu JJ, Kenerson HL, Harris WP, Park JO, Yeung RS. mTORC1 and FGFR1 signaling in fibrolamellar hepatocellular carcinoma. Mod Pathol. 2014 Jun 13. doi: 10.1038/modpathol.2014.78. [Epub ahead of print] PMID: 24925055.
Sham JG, Kievit FM, Grierson JR, Miyaoka RS, Yeh MM, Zhang M, Yeung RS, Minoshima S, Park JO. Glypican-3-targeted 89Zr PET imaging of hepatocellular carcinoma. J Nucl Med. 2014 May;55(5):799-804. doi: 10.2967/jnumed.113.132118. Epub 2014 Mar 13. PMID: 24627434
Kenerson HL, Yeh MM, Kazami M, Jiang X, Riehle KJ, McIntyre RL,Park JO, Kwon S, Campbell JS, Yeung RS. Akt and mTORC1 have different roles during liver tumorigenesis in mice. Gastroenterology. 2013 May;144(5):1055-65. doi: 10.1053/j.gastro.2013.01.053. Epub 2013 Jan 30. PMID: 23376645
Wang K, Park JO, Zhang M. Treatment of glioblastoma multiforme using a combination of small interfering RNA targeting epidermal growth factor receptor and β-catenin. J Gene Med. 2013 Jan;15(1):42-50. doi: 10.1002/jgm.2693. PMID: 23319157.
Wolf PS, Park JO, Bao F, Allen PJ, DeMatteo RP, Fong Y, Jarnagin WR, Kingham TP, Gönen M, Kemeny N, Shia J, D'Angelica MI. Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience. J Am Coll Surg. 2013 Jan;216(1):41-9. doi: 10.1016/j.jamcollsurg.2012.08.030. Epub 2012 Oct 5. PMID: 23041049
Massarweh NN, Park JO, Yeung RS, Flum DR. Comparative assessment of the safety and effectiveness of radiofrequency ablation among elderly medicare beneficiaries with hepatocellular carcinoma. Ann Surg Oncol. 2012 Apr;19(4):1058-65. doi: 10.1245/s10434-011-2067-7. Epub 2011 Sep 27. PMID: 21947695
Veiseh O, Kievit FM, Mok H, Ayesh J, Clark C, Fang C, Leung M, Arami H, Park JO, Zhang M. Cell transcytosing poly-arginine coated magnetic nanovector for safe and effective siRNA delivery. Biomaterials. 2011 Aug;32(24):5717-25. Epub 2011 May 13. PMID: 21570721
Massarweh NN, Park JO, Bruix J, Yeung RS, Etzioni RB, Symons RG, Baldwin LM, Flum DR. Diagnostic imaging and biopsy use among elderly medicare beneficiaries with hepatocellular carcinoma. J Oncol Pract. 2011 May;7(3):155-60. doi: 10.1200/JOP.2010.000116. PMID: 21886495
Park JO, Yeh MM. Clinical significance and implication of neoangiogenesis in hepatocellular carcinoma. J Gastroenterol Hepatol. 2011 May;26(5):792-3. doi: 10. 1111/j. 1440-1746. 2011. 06681. PMID: 21488943
Park JO, Stephen Z, Sun C, Veiseh O, Kievit FM, Fang C, Leung M, Mok H, Zhang M. Glypican-3 targeting of liver cancer cells using multifunctional nanoparticles. Mol Imaging. 2011 Feb;10(1):69-77. PMID: 21303616
Veiseh O, Kievit FM, Fang C, Mu N, Jana S, Leung MC, Mok H, Ellenbogen RG, Park JO, Zhang M. Chlorotoxin bound magnetic nanovector tailored for cancer cell targeting, imaging, and siRNA delivery. Biomaterials. 2010 Nov;31(31):8032-42. Epub 2010 Jul 31. PMID: 20673683
Park JO, Lopez CA, Gupta VK, Brown CK, Mauceri HJ, Darga TE, Manan A, Hellman S, Posner MC, Kufe DW, Weichselbaum RR. Transcriptional control of viral gene therapy by cisplatin. J Clin Invest. 2002 Aug;110(3):403-10.